证券代码：688203 证券简称：海正生材 公告编号：2025-42 浙江海正生物材料股份有限公司 关于公司董事辞职暨选举职工董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、董事/高级管理人员离任情况 (一) 提前离任的基本情况 是否存在 是否继续在上 | | | 原定任期 | | 具体职务 未履行完 | | --- | --- | --- | --- | --- | | 姓名 | 离任职务 | 离任时间 | 离任原因 | 市公司及其控 | | 原定任期 | 具体职务 | 未履行完 | | --- | --- | --- | | 到期日 | （如适用） | 毕的公开 | | | 股子公司任职 | | | | 承诺 | | 人事调整 张嘉滢 董事 及工作需 否 不适用 否 浙江海正生物材料股份有限公司（以下简称"公司"）董事会近日收到张嘉 滢女士提交的书面辞职报告。因人事调整及工作需要，张嘉滢女士辞去公司董事 职务，张嘉滢女士辞职后将不再担任公司任何职务。公司于 2025 年 7 月 31 日召 ...

证券日报网讯 7月31日晚间，海正生材发布公告称，公司2025年第二次临时股东会于2025年7月31日召 开，审议通过了《关于修订部分公司治理制度的议案》等。 （文章来源：证券日报） ...

证券日报网讯 7月31日晚间，海正生材发布公告称，公司董事会近日收到张嘉滢女士提交的书面辞职报 告。因人事调整及工作需要，张嘉滢女士辞去公司董事职务，张嘉滢女士辞职后将不再担任公司任何职 务。公司于2025年7月31日召开职工代表大会，经全体与会职工代表表决，同意选举叶海燕女士担任公 司第七届董事会职工代表董事。 （文章来源：证券日报） ...

浙江海正生物材料股份有限公司 证券代码：688203 证券简称：海正生材 公告编号：2025-42 关于公司董事辞职暨选举职工董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 浙江海正生物材料股份有限公司（以下简称"公司"）董事会近日收到张嘉 滢女士提交的书面辞职报告。因人事调整及工作需要，张嘉滢女士辞去公司董事 职务，张嘉滢女士辞职后将不再担任公司任何职务。公司于 2025 年 7 月 31 日召 开职工代表大会，经全体与会职工代表表决，同意选举叶海燕女士担任公司第七 届董事会职工代表董事。 一、董事/高级管理人员离任情况 (一) 提前离任的基本情况 | 姓名 | 离任职务 | | 离任时间 | 原定任期 | | 是否继续在上 | 具体职务 | 是否存在 未履行完 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 到期日 | 离任原因 | 市公司及其控 股子公司任职 | （如适用） | 毕的公开 承诺 | | 张嘉 ...

证券代码：688203 证券简称：海正生材 公告编号：2025-41 浙江海正生物材料股份有限公司 2025年第二次临时股东会决议公告 （二） 股东会召开的地点：浙江省台州市台州湾新区台州湾大道 188 号浙江海 诺尔生物材料有限公司会议室 （三） 出席会议的普通股股东及其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 71 | | --- | --- | | 普通股股东人数 | 71 | | 2、出席会议的股东所持有的表决权数量 | 120,858,933 | | 普通股股东所持有表决权数量 | 120,858,933 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 60.0703 | | 例（%） | | | | | 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 7 月 31 日 注：截至本次股东会股权登记日，公司总股本为 202,678,068 股，其中公司回购专用账户 ...

北京康达（杭州）律师事务所 BEIJING KANGDA（HANGZHOU）LAW FIRM 杭州市上城区西子国际中心 2 号楼 1501-1503 室 邮编：310020 电话/Tel.:0571-85779929 传真/Fax:0571-85779955 网址/Website:www.kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 昆明 关于浙江海正生物材料股份有限公司 2025 年第二次临时股东会的法律意见书 康达(杭州)股会字【2025】第 0025 号 北京康达（杭州）律师事务所 关于浙江海正生物材料股份有限公司 2025 年第二次临时股东会的 法律意见书 康达(杭州)股会字【2025】第 0025 号 二〇二五年七月 北京康达（杭州）律师事务所 海正生材 2025 年第二次临时股东会法律意见书 北京康达（杭州）律师事务所 致：浙江海正生物材料股份有限公司 北京康达（杭州）律师事务所（下称"本所"）接受浙江海正生物材料股份 有限公司（下称"海正生材"或"公司"）委托，指派 ...

Core Viewpoint - Haizheng Biomaterials (688203.SH) has faced significant challenges after its initial public offering, with declining profits and increasing competition in the polylactic acid (PLA) market despite being a pioneer in the industry [3][4][7]. Financial Performance - The company reported its best profit in 2022, but subsequent years have seen a decline in net profit, with decreases of 7.41% in 2023, 18.47% in 2024, and a staggering 97.45% in Q1 2025 [4][6]. - Revenue for 2024 was 845 million, a year-on-year increase of 12.2%, but the gross margin fell to 12.71% in 2024, down 0.33 percentage points from 2023 [20][23]. Market Position and Competition - Haizheng Biomaterials is the first domestic and second global company to commercialize PLA production, holding a leading market share in China [7][47]. - The industry has seen rapid capacity expansion following domestic technological breakthroughs, leading to potential oversupply and reduced profitability [7][40][46]. Production Capacity and Delays - The company has faced delays in expanding its production capacity, with the initial plan for a 150,000-ton annual capacity project being adjusted to a phased implementation due to market conditions [24][26][27]. - As of the end of 2024, the first phase of the project was 70% complete, while the second phase was only 15% complete, with further delays anticipated [27]. Industry Dynamics - The PLA industry benefits from government support for biodegradable materials, with PLA projected to account for 37.1% of the bio-based materials market by 2024 [28][30]. - However, demand is primarily driven by policy rather than market forces, leading to challenges in adoption due to higher costs compared to traditional plastics [38][49]. Product Development - The company has developed various PLA grades tailored for different applications, including 3D printing, which saw a 185.67% increase in sales in 2024 [34][35]. - The revenue from modified PLA resins reached 187 million in 2024, indicating a focus on diversifying product offerings [35]. Future Outlook - Despite the promising market for biodegradable materials, the rapid expansion of production capacity across the industry poses a risk of oversupply, reminiscent of the solar energy sector's challenges [49].

Investment Rating - The report rates the industry as "Outperform" [1] Core Insights - BYD has achieved a global milestone by realizing L4-level intelligent parking, allowing drivers to be hands-free under specific conditions, with liability on automobile companies [5][12] - xAI has released Grok-4, a next-generation large model that has seen a tenfold increase in reasoning capabilities compared to its predecessor, excelling in various benchmarks and outperforming human graduate-level academic abilities [5][13] - The Ministry of Industry and Information Technology has issued the 2025 Work Points for Integration of Informatization and Industrialization, emphasizing new industrialization and supporting software development, AI empowerment, and digital transformation [5][14] Summary of Related Companies - Recommended targets include: Empyrean Technology, Dameng Data, Beijing Kingsoft Office Software, Newland Digital Technology, Jiangsu Tongxingbao Intelligent Transportation Technology Co., Ltd., Kingdee International Software Group, Hehe Information; related target: Wuxi Unicomp Technology Co., Ltd. [5][11] - BYD's advantages in assisted driving and manufacturing ensure safety for users in the Chinese market, boosting trust in intelligent parking [5][12] - Grok-4 has demonstrated strong capabilities in real-world applications, including significant improvements in voice response speed and performance in complex tasks across various industries [5][13]

Group 1 - The company will hold its second extraordinary general meeting of shareholders in 2025 to discuss various proposals, including the cancellation of the supervisory board and amendments to the company's articles of association [2][8][10] - The meeting will ensure the orderly conduct of proceedings and protect the rights of shareholders, with specific rules for attendance and participation [3][4][5] - The company has proposed to replace the supervisory board's functions with the audit committee of the board of directors, which will require amendments to relevant governance documents [8][10] Group 2 - The company has nominated Wang Fang as a candidate for a non-independent director position on the board, following the resignation of Wang Haiyan due to work commitments [12][13] - Wang Fang has a background in finance and has held various positions in financial institutions and state-owned enterprises, which aligns with the company's governance needs [12][13] - The election of Wang Fang will also lead to her appointment to the remuneration and assessment committee of the board, ensuring compliance with governance structure [13][14]

海正生材 2025 年第二次临时股东会会议资料 证券代码：688203 证券简称：海正生材 浙江海正生物材料股份有限公司 2025 年第二次临时股东会会议资料 二○二五年七月三十一日 海正生材 2025 年第二次临时股东会会议资料 浙江海正生物材料股份有限公司 2025 年第二次临时股东会资料目录 | 2025 | 年第二次临时股东会会议须知 2 | | --- | --- | | 2025 | 年第二次临时股东会会议议程 4 | | | 议案一：关于取消监事会并修订《公司章程》及其附件的议案 6 | | | 议案二：关于修订部分公司治理制度的议案 7 | | 2.01 | 关于修订《浙江海正生物材料股份有限公司防止大股东及关联方占用公司资 | | | 金管理制度》的议案 | | 2.02 | 关于修订《浙江海正生物材料股份有限公司累积投票制实施细则》的议案 | | 2.03 | 关于修订《浙江海正生物材料股份有限公司独立董事工作制度》的议案 | | 2.04 | 关于修订《浙江海正生物材料股份有限公司董事会审计委员会工作细则》的 | | 议案 | | | 2.05 | 关于修订《浙江海正生物材料股份有限公司 ...